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A B S T R A C T
The obligate intracellular bacterium, Chlamydia pneumoniae, has been identified as a risk factor for several
chronic inflammatory diseases in addition to respiratory tract infections. The dissemination of C. pneumoniae
from respiratory tract to secondary sites of infection occurs via infected monocyte / macrophage line cells, in
which C. pneumoniae can persist as an antibiotic-refractory phenotype. To allow more detailed studies on the
epithelium-monocyte/macrophage transition of the infection, new in vitro bioassays are needed. To this end, a
coculture system with human continuous cell lines was established. Respiratory epithelial HL cells were infected
with C. pneumoniae and THP-1 monocytes were added into the cultures at 67 h post infection. After a 5 h co-
culture, THP-1 cells were collected with a biotinylated HLA antibody and streptavidin-coated magnetic beads
and C. pneumoniae genome copy numbers in THP-1 determined by quantitative PCR. The assay was optimized for
cell densities, incubation time, THP-1 separation technique and buffer composition, and its robustness was
demonstrated by a Z' value of 0.6. The mitogen-activated protein kinase (MAPK) inhibitors: SP600125 (JNK
inhibitor), SB203580 (p38 inhibitor) and FR180204 (ERK inhibitor) suppressed the transfer of C. pneumoniae
from HL to THP-1 cells, making them suitable positive controls for the assay. Based on analysis of separate steps
of the process, the MAPK inhibitors suppress the bacterial entry to THP-1 cells. The transfer of C. pneumoniae
from epithelium to phagocytes represents a crucial step in the establishment of persistent infections by this
pathogen, and the presented methods enables future studies to block this process by therapeutic means.
1. Introduction
Chlamydia pneumoniae is a gram-negative, obligate intracellular
bacterium, whose primary site of infection is the respiratory tract (Kuo
et al., 2015). It causes various acute illnesses such as pharyngitis, si-
nusitis and it is a cause of 10% of community acquired pneumonia
(CAP) (Kuo et al., 1995). C. pneumoniae is a ubiquitous bacterium and
majority of adults have been infected, at least once, during their life-
time. In addition to respiratory tract infections, C. pneumoniae has been
identified as a risk factor for several chronic inflammatory diseases such
as asthma (Smith-Norowitz et al., 1971; Webley and Hahn, 2017),
atherosclerosis (Campbell and Kuo, 2004; Filardo et al., 2015) and
Alzheimer's disease and neurovascular complications (Little et al.,
2004; Balin PhD et al., 2017; Richard, 2018).
Serological findings (Filardo et al., 2015; Saikku et al., 1988) and
histological demonstration of the presence of C. pneumoniae in athero-
sclerotic plagues (Luque et al., 2012; Shor and Phillips, 2000) have
triggered a spectrum of experimental studies on the role of C. pneu-
moniae in the etiology of cardiovascular diseases. Established animal
models with mice and rabbits have demonstrated the induction of
atherosclerotic plague development (Muhlestein, 2000; Sorrentino
et al., 2015), endothelial dysfunction (Huang et al., 2012), accelerated
hyperlipidemia (Blessing et al., 2001) and thus promotion of the
atherosclerosis development by the infection. C. pneumoniae DNA has
also been detected from post mortem Alzheimer's brain samples (Balin
et al., 1998) and the infection has been found to induce amyloid plague
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formation in animal models for Alzheimer's disease (Little et al., 2004;
Boelen et al., 2007).
C. pneumoniae has a unique biphasic lifecycle which involves ex-
tracellular, metabolically less active (Grieshaber et al., 2018), infectious
form, elementary body (EB) and intracellular, metabolically active,
replicative form, reticulate body (RB) (Elwell et al., 2016). To drive
bacterial replication, EBs attach and internalize into the host cell by
endocytosis. Within the lipid vacuole called inclusion, EBs differentiate
to RBs and start to multiply. At 48 to 72 h post infection RBs asyn-
chronously reorganize back to EBs which are released from the cell
through host cell lysis or extrusion, the latter of which leaves the host
cell intact. Besides the productive chlamydial replication cycle, C.
pneumoniae can enter into a reversible dormant state. Showing analogy
to persister subpopulations more recently found within other patho-
genic bacteria (Balaban et al., 2019), these viable but non-replicative
chlamydial cells are referred as aberrant bodies (ABs) (Panzetta et al.,
2018). Persistent C. pneumoniae maintains the capability to modulate
host cells signaling pathways, resulting in the activation of host tyrosine
kinases and nuclear factor- κB (NF-κB) signaling. It produces outer
membrane vesicles containing molecules such as high-temperature re-
quirement A (HtrA) proteases targeting the host cells (Frohlich et al.,
2014; Backert et al., 2018; Ong et al., 2013). The persistent state is
triggered by various stress signals and it is particularly prominent
within the infections of immune cells such as monocytes and macro-
phages (Beagley et al., 2009).
In the course of in vivo infections, C. pneumoniae first targets re-
spiratory tract epithelium, but may later disseminate to other body
sites. While direct transfer from olfactory tract to central nervous
system has been proposed (Fulop et al., 2018), transfer to local pha-
gocytes and further to peripheral blood mononuclear cells is considered
the primary route for C. pneumoniae systemic dissemination (Moazed
et al., 1998; Yang et al., 1995; Gieffers et al., 2004). The epithelium –
monocyte/macrophage transition is crucial for the role of C. pneumoniae
as an etiologic agent in chronic inflammatory diseases at various body
sites. Besides acting as dissemination vehicles, monocytes and macro-
phages play an important role in promoting a long-lasting inflammatory
state associated with persistent C. pneumoniae infections (Beagley et al.,
2009). C. pneumoniae infected monocytes produce various cytokines
such as interleukin (IL)-1β, IL-6, IL-8 (Lim et al., 2014), IL-10 (Mamata
et al., 2007), IL-12 (Kortesoja et al., 2019) and tumor necrose factor
(TNF)-α (Mamata et al., 2007) and the infection also induces reactive
oxygen species (ROS) production (Mouithys-Mickalad et al., 2004) and
activates NLRP3 inflammasome (Itoh et al., 2014). A major hallmark of
C. pneumoniae persistence is its antibiotic-refractory nature. It has been
reported by us and others that C. pneumoniae cannot be eradicated from
monocytes by antibiotics (Airenne et al., 1999; Taavitsainen et al.,
2020; Gieffers et al., 2001). If the transfer of C. pneumoniae from lung
epithelium to monocytes and macrophages could be inhibited the
chronic proinflammatory state could be reduced and progression of the
chronic inflammatory diseases such as atherosclerosis and Alzheimer's
disease may be diminished.
Despite its significance in the establishment of long-lasting infec-
tions, bioassays suitable for in vitro studies on the transfer of C. pneu-
moniae from epithelium to phagocytes have not been described. In
previous studies focusing on interactions of different cell populations in
the course of chlamydial infections, the interplay between vascular wall
cells and monocytes has been addressed by coculture systems. A co-
culture between infected human arterial endothelial cells (HMECs) (Lin
et al., 2000), human umbilical vein endothelial cells (HUVECs) or
coronary artery smooth muscle cells (CASMCs) (Puolakkainen et al.,
2003) and uninfected U937 monocytic cells have been reported to en-
hance the C. pneumoniae infection in vascular wall cells. It has also been
demonstrated that infection transfers into HMECs and CASMCs from
infected U937 cells. With a related pathogen Chlamydia trachomatis
coculture setups have been established with epithelial cells and
monocytes (Mpiga et al., 2006; Mpiga and Ravaoarinoro, 2006). These
studies have, however, focused on cytokine production and other im-
munological outcomes of chlamydial infections.
Standard techniques for detecting and quantifying C. pneumoniae in
biological samples include immunofluorescence applying Chlamydia-
specific anti-lipopolysaccharide (LPS) antibody and polymerase chain
reaction (PCR). Chlamydial inclusions are easily visualized in cultured
monolayer cells allowing chlamydial replication, but the irregular size
and morphology of the inclusions in nonpermissive cells such as
monocytes and macrophages limits the use of staining techniques
(Poikonen et al., 2010). Furthermore, genetic transformation of C.
pneumoniae has become feasible only very recently (Shima et al., 2018)
and therefore bioassays with reporter gene inserts are generally not
available. Currently the susceptibility screening of antichlamydial drug
candidates is based on their impact on chlamydial inclusion counts in
epithelial cells, which detects only the net chlamydial load after one
productive infection cycle. This standard MIC test thus leaves the per-
sistent infections unconsidered and does not provide information on the
maturation or infectivity of the produced EBs. Due to the fact that
persistent C. pneumoniae cannot be eradicated by traditional antibiotics,
new antichlamydial compounds, as well as new methods to evaluate
them, are needed. In addition to direct bacteriostatic or bacteriocidic
modes of action, assessing the candidate compounds for their capability
to inhibit the transfer of C. pneumoniae between cell populations would
provide a valuable means for compound profiling and prioritizing. Here
we present a robust coculture model to study the transfer of C. pneu-
moniae from lung epithelial, HL cells to THP-1 monocytes. In addition, a
set of assays focusing on individual steps within the epithelium –
monocyte transition is applied to study the targets of transition in-
hibitors. By this means we found that MAPK inhibitors reduce the in-
ternalization of C. pneumoniae to monocytes and decrease the transfer of
infection between epithelial cells and monocytes.
2. Materials and methods
2.1. Compounds
C-Jun N-terminal kinase (JNK) inhibitor SP600125, p38 inhibitor
SB203580 and extracellular signal-regulated kinase (ERK) inhibitor
FR180204 (Table 1) were purchased from Tocris Bioscience (Bristol,
Table 1
MAPK-inhibitors applied in this study.
Name Target kinase Structure
SP600125 c-Jun N-terminal
kinases (JNKs)
SB203580 p38 mitogen
activated protein
kinases
FR180204 Extracellular signal-
regulated kinases
(ERK)
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UK), dissolved in dimethyl sulfoxide (DMSO) as 20 mM stock solution
and used as 10 μM working concentration in all the experiments. The
final DMSO concentration in the assays was 0.05%.
2.2. Cell culture
Cell cultures were maintained and incubated at 37 °C, 5% CO2 and
95% relative humidity. Cell numbers for all experiments were de-
termined by counting the cells with hemocytometer. Human respiratory
tract epithelial, human lung (HL) cells (Kuo and Grayston, 1990), ob-
tained from professor Pekka Saikku / National Institute of Health and
University of Oulu, Finland, were cultured in RPMI 1640 cell culture
medium (BioWhittaker, Lonza, Basel, Switzerland) supplemented with
2 mM L-glutamine (BioWhittaker), 7.5% fetal bovine serum (FBS)
(BioWhittaker) and 20 mg/ml Gentamicin (Fluka, Buchs, Switzerland).
Human monocytic cell line THP-1 (ATCC TIB202) was cultured in
RPMI 1640 (Dutch edition) cell culture medium (Gibco, Invitrogen,
Thermo Fisher Scientific, Paisley, UK) supplemented with 2 mM L-glu-
tamine (BioWhittaker), 10% FBS (BioWhittaker), 0.05 mM 2-mercap-
toethanol (Gibco) and 20 μg/ml Gentamicin (Fluka).
2.3. C. pneumoniae infection
C. pneumoniae cardiovascular isolate CV-6 (Maass et al., 1998) was
obtained from professor Matthias Maass (Paracelsus Medical Uni-
versity, Salzburg, Austria) and propagated in HL cells. Cells were in-
oculated with C. pneumoniae and incubated in cell culture medium
(RPMI 1640 supplemented with 7.5% FBS, 2 mM L-glutamine, 0.6 μg/
ml cycloheximide (CHX), 10 μg/ml gentamicin, 100 μg/ml strepto-
mycin, 3.75 μg amphotericin B). After 72 h, the HL cells were lyzed, the
cell debris was removed by centrifugation (10 min, 500 xg, 4 °C) and
chlamydial EBs collected by pelleting (1 h at 21000 x g, 4 °C). The EBs
were resuspended into sucrose-phosphate-glutamic acid (SPG) (Airenne
et al., 1999) and stored at −80 °C. The EB stock titers, expressed as
inclusion forming units (IFUs) per ml were determined by infecting the
HL cells cultured on coverslips with 10-fold serial dilutions and by
counting the inclusions after 72 h.
For experiments, the HL cells were infected by seeding the cells into
24-well plates at a density of 3 × 105 cells/ml and incubated overnight.
The cell monolayer was inoculated with C. pneumoniae with a multi-
plicity of infection (MOI) 1 and the plate was centrifuged at 550 xg for
1 h at room temperature and then incubated at 37 °C an additional
hour. The inoculum was removed and the cells were incubated 67 to
72 h in cell culture medium with or without the MAPK inhibitors.
2.4. HL - THP-1 coculture
HL cells were seeded into 24-well plates at a density of 3 × 105
cells/ml and infected with C. pneumoniae MOI 1 as described above. At
67 h post infection, HL cells were washed with 1 ml of sterile phosphate
buffered saline (PBS) and 3 × 105 THP-1 cells were added into the
wells on top of HL monolayer in THP-1 cell culture medium, and cells
were incubated together for 5 h (Fig. 1). THP-1 cells were then collected
by pipetting and centrifuged at 300 xg, 5 min. Supernatants were dis-
carded and cell pellets were suspended with 100 μl of degassed buffer
(1% BSA, 5 mM ethylenediaminetetraacetic acid (EDTA) in PBS). Cells
were incubated for 15 min on ice with 1:100 dilution of biotin con-
jugated HLA-A2 antibody (Biolegend, San Diego, US). One ml of buffer
was added and the cells were centrifuged at 300 xg for 5 min. After
washing the excess antibody, cells were incubated on ice another
15 min with 1:100 dilution streptavidin conjugated MojoSort nano-
beads (Biolegend) in 100 μl of buffer. Then, cells were washed with
1 ml of buffer, centrifuged at 300 xg for 5 min and pellets were re-
suspended in 500 μl of buffer. LS column (Miltenyi Biotec, US) was
placed in the magnetic field of the MidiMACS separator (Miltenyi
Biotech) and it was prepared with 3 ml of buffer. Then the sample was
loaded into MACS magnetic separation system and the column was
washed with 4 × 3 ml of buffer. The column was released from the
magnetic field and the sample was eluted from the column with 4 ml of
buffer by using the plunger. After that the cells were centrifuged at 300
xg, 5 min, and resuspended in 1 ml of buffer. The collected THP-1 cells
were then counted and samples were frozen at −20 °C for further DNA
extraction.
2.5. Optimizing the coculture protocol
In the course of optimization of the coculture protocol, two alter-
native cell densities (3 × 105 and 4 × 105 cells/well) in the 24-well
plate were evaluated. The concentration of 3 × 105 cells/ml resulted in
fewer detached HL cells and was thus chosen for further use.
The composition of the buffer used for the column separation was
also optimized. 2 mM EDTA and 1% BSA in PBS improved the yield and
viability of the THP-1 cells, after the separation, compared to pure PBS
or PBS with EDTA. Degassing of the chosen buffer to remove excess
oxygen and air bubbles before use also improved the results sig-
nificantly. In addition to washing steps, the buffer was used to prepare
the LS column before loading the sample, which improved the yield of
THP-1 cells.
To separate the THP-1 monocytes from HL cells, three different
methods were evaluated (Table 2). First the phagocytic activity of the
monocytes was exploited by allowing a spontaneous ingestion of the
magnetic beads. After incubation, cells were trypsinized and separated
with MACS magnetic separation system without antibodies. After the
separation, there were still epithelial cells in the positive fraction and
also THP-1 cells were found in the waste. The phagocytosis of the beads
by THP-1 cells was thus neither totally specific nor efficient. Further-
more, the viability of the THP-1 cells after the separation was low,
0–35%.
Thus, HLA-A2 antibody was applied for the separation. After co-
culture all of the cells were collected by trypsinization, incubated with
the antibody and magnetic beads and were then loaded into MACS
magnetic separation system. After washing the column with the buffer,
there was still a large amount of epithelial cells in the samples, resulting
in the need for further optimization to avoid excessive washing steps.
In the final protocol THP-1 cells were collected from the wells by
pipetting and the remaining HL cells were more effectively removed by
HLA-A2 antibody labeling. To allow the THP-1 suspension removal
from the wells by pipetting, the incubation time of the actual coculture
Fig. 1. A workflow for collecting THP-1 cells by magnetic separation. THP-1
cells were collected by pipetting from wells with HL monolayers and pelleted by
centrifugation. THP-1 cells were labeled with a biotinylated HLA-A2 antibody
and streptavidin-magnetic beads. Cells were placed into LS columns which were
placed into MidiMACS magnetic separator. Remaining, unlabeled HL cells that
might have come along with the THP-1 cells suspension were washed away
from the sample and only THP-1 cells were collected.
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was limited to 5 h, providing a time frame with efficient bacterial
transfer without extensive adherence of the THP-1 cells to the HL
monolayer.
2.6. Quantitative PCR
Total DNA from the THP-1 cells was extracted with GeneJet
Genomic DNA purification kit (Thermo Fisher Scientific, Massachusetts,
USA) according to manufacturer's instructions and the DNA con-
centration in the samples was measured with NanoDrop (Thermo Fisher
Scientific). C. pneumoniae genome copy numbers (GE) were quantified
based on the bacterial OmpA gene using Step One Plus Real-Time PCR
system (Thermo Fisher Scientific). The primers for C. pneumoniae OmpA
gene were 5′-TCC GCA TTG CTC AGC C-3′ (forward) and 5′-AAA CAA
TTT GCA TGA AGT CTG AGA-3′ (reverse) (Tondella et al., 2002). The
reactions were performed in 96-well MicroAmp optical plates (Thermo
Fisher Scientific) by adding 20 μg DNA to 10 μl of master mix. Total
reaction volume was 20 μl. Conditions in thermal cycle were 95 °C for
20 s and 40 cycles of 95 °C for 3 s and 60 °C for 30 s. In all PCR runs
negative control samples without any template was included. Standard
curves for GE number determination were generated by serial dilution
of purified EB stocks with known titer.
2.7. Quantification of EB production and EB exit determination
HL cells were seeded into 24-well plates at a density of
3 × 105 cells/ml and infected with C. pneumoniae at MOI1 as described
above and incubated for 67 h (passage 1). The MAPK inhibitors were
added to the wells and incubated for further 5 h. Supernatants con-
taining the released EBs were collected, EBs were pelleted by cen-
trifugation (21,000 g, 1 h, 4 °C) and resuspended in cell culture
medium. EBs residing inside HL monolayers were also collected by
scraping the cells off from the wells and lysing them with glass beads.
After that, the EBs from the supernatant and cell lysate were inoculated
onto to the fresh HL monolayers (passage 2) as described above for pure
EBs. At 3 h post infection cells were collected by scraping, centrifuged
at 300 xg for 5 min and resuspended in PBS. Total cellular DNA was
extracted with GeneJet Genomic DNA purification kit, and quantifica-
tion of C. pneumoniae genome copy numbers was performed using Step
One Plus Real-Time PCR system as described above.
2.8. EB infectivity assay
To study the effect of MAPK inhibitor treatment on C. pneumoniae
EB infectivity as previously described (Hanski et al., 2016a), 3 × 105
EBs, diluted from stock solution in 100 μl THP-1 cell culture medium,
were incubated with MAPK inhibitors for 2 h on ice. Then 3 × 105 THP-
1 cells in 900 μl, were added into the suspension and the samples fur-
ther incubated for 2 h at 37 °C. Cells were collected, the supernatant
was removed, and the pellet was resuspended in PBS. Centrifugation
was repeated and cells were stored at −20 °C. DNA was extracted with
GeneJet Genomic DNA purification kit, and quantification of C. pneu-
moniae genome copy numbers was performed using Step One Plus Real-
Time PCR system as described above.
2.9. EB internalization assay
The C. pneumoniae entry to the monocytes was studied with a pro-
tocol modified from a previously published work (Hanski et al., 2016b).
To evaluate whether MAPK inhibitors have an effect on internalization
of C. pneumoniae, 3 × 105 THP-1 cells were incubated with 3 × 105 EBs
(MOI1) in 100 μl of cell culture medium with MAPK inhibitors for 2 h at
37 °C. Then, to remove any uninternalized EBs, the cell pellet were
resuspended in 1 ml of PBS and cells collected again by centrifuging at
300 g, 5 min. Total cellular DNA was extracted with GeneJet Genomic
DNA purification kit (Thermo Fisher Scientific), and quantification of C.
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pneumoniae genome copy numbers was performed using Step One Plus
Real-Time PCR system as described above.
3. Data analysis
Statistical analyses were performed using SPSS Statistics 25 soft-
ware. Differences between the study groups were calculated by two-
tailed student's t-test or by One-way ANOVA and Dunnett's post hoc
test. Statistical significances are presented as P values, which<0.05
were considered as significant. The formula used for Z' value calculation
was = +Z SD of sample SD of controlmean of the sample mean of the control3 3 . The n values of each experi-
ment are presented in corresponding figure legend. At least 4 biological
replicates (data from separate cell cultures) and two technical replicates
(data derived from the same biological replicate) were applied.
4. Results
4.1. Transfer of C. pneumoniae from epithelial cells to monocytes in a
coculture system
In the human body, C. pneumoniae transfers between epithelial cells
and phagocytes (Moazed et al., 1998; Gieffers et al., 2004). To study
this phenomenon in vitro, a coculture model applying human re-
spiratory epithelial and monocytic cell lines was established. The epi-
thelial HL cells were infected with C. pneumoniae and at 67 h post in-
fection, representing a late stage of the replication cycle of C.
pneumoniae, uninfected THP-1 monocytes were added to the wells in a
ratio of 1:1. After 5 h incubation, THP-1 cells were collected and se-
parated from HL cells by applying the biotinylated HLA-A2 antibody
and streptavidin coated magnetic beads. The collected THP-1 cells were
lysed, DNA extracted and the genome copy numbers of C. pneumoniae in
THP-1 cells were determined. Fig. 2 presents a typical signal window
obtained with the assay. There was a significant (p = .001) difference
in C. pneumoniae genome copy numbers in THP-1 cells between the
control and infection samples. In samples collected from wells with
infected HL cells the average genome copy number was 28,809. In
control samples collected from cultures with uninfected HL cells, minor
nonspecific amplification yielded a in apparent GE numbers of 13.4,
more than 2200 times smaller than in infection samples (S/B = 2209).
While 15–20% day-to-day variation in C. pneumoniae genome copy
numbers was observed in THP-1 lysates, the variation within biological
and technical replicates of each experiments was only 5–10%. Typical Z'
values of 0.6 were achieved, which can be considered excellent for an
assay involving three biological variables, i.e. two human and one
bacterial cell population.
4.2. MAPK inhibitors suppress the transfer of C. pneumoniae from the HL
epithelial cells to THP-1 cells
To find suitable positive controls for the assay, the MAPK inhibitors
SP600125, SB203580 and FR180204 were studied on their potential
effect on the transfer of C. pneumoniae between the cells in the coculture
model. Applying the final concentration of 10 μM, the MAPK inhibitors
were added to the culture simultaneously with THP-1 cells. After 5 h,
THP-1 cells were collected and separated from HL cells. Based on C.
pneumoniae genome copy numbers determined from THP-1 cells
(Fig. 3), all MAPK inhibitors had a statistically significant inhibitory
effect on the transfer of the bacteria. The JNK inhibitor SP600125 de-
creased the transfer by 69.0% (p = .00001), the p38 inhibitor
SB203580, by 54.1% (p = .0002) and the ERK inhibitor FR180204, by
36.8% (p = .009), respectively.
4.3. Impact of MAPK inhibitors on C. pneumoniae EB production in
epithelial cells
For step by step analysis of the events occurring within the epi-
thelium to monocyte transition of C. pneumoniae and elucidation of the
processes affected by the MAPK inhibitors, we next conducted a set of
experiments on EB quantities, release and internalization. First, we
determined the impact of 5 h exposure of the HL cell infection (starting
at 67 h p.i.) to the MAPK inhibitors on EB quantities inside HL cells as
well as those released in the culture supernatants. Quantity of EBs
produced in the end of replication cycle inherently affects the infection
transfer and changes in EB quantities are thus a possible explanation for
the pharmacological effects targeting infection transfer. The 5 h in-
cubation time was selected as comparable for the time allowing infec-
tion transfer during the coculture experiments. There was no statisti-
cally significant effect (p = .097) by any of the MAPK inhibitors on C.
pneumoniae EB quantities inside HL cells. Regarding the quantities of
EBs released from HL cells to culture supernatant, the P38 inhibitor
SB203580 and ERK inhibitor FR180204 had no effect on the release of
the EBs but JNK inhibitor SP600125 increased the quantities of C.
pneumoniae EBs in the supernatants (p = .004) (Fig. 4).
4.4. Impact of MAPK inhibitors on the infectivity of C. pneumoniae EBs
Besides potential effect on EB quantities and release, compounds
affecting the epithelial-monocytic transition may target the released
EBs in the extracellular space prior their internalization to monocytes.
Even though targeting bacterial processes is not likely for the mam-
malian MAPK inhibitors, this could occur via undescribed off-target
Fig. 2. The transfer of C. pneumoniae from epithelium to monocytes. THP-1 cells
were cultured with infected and uninfected HL cells. After 5 h, THP-1 cells were
collected and C. pneumoniae genome copy numbers inside THP-1 cells was
determined by qPCR. Data are presented as log10 values± SEM of C. pneu-
moniae genome numbers Statistical significance is determined by two-tailed
Student's t-test and presented as marks of P values:< 0.05: *;< 0.01:
**;< 0.001: ***. N = 4 independent biological replicates.
Fig. 3. MAPK inhibitors suppress the transfer of C. pneumoniae from HL to THP-
1 cells. THP-1 cells were cultured with infected and uninfected HL cells in
presence of MAPK inhibitors SP600125, SB203580 and FR180204. After 5 h,
THP-1 cells were collected and C. pneumoniae genome copy numbers inside
THP-1 cells were determined by qPCR. Data are normalized on the infection
control and shown as mean ± SEM of C. pneumoniae genome copy numbers.
Statistical significance is determined by One-way ANOVA and Dunnett's post
hoc test and presented as marks of P values:< 0.05: *;< 0.01: **;< 0.001:
***. n = 4 independent biological replicates.
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effects and was thus included in the study. As expected, none of the
MAPK inhibitors had an effect (p = .82) on the infectivity of C. pneu-
moniae EBs after 2 h exposure (data not shown).
4.5. Impact of MAPK inhibitors on the internalization of C. pneumoniae
into THP-1 monocytes
Finally, the impact of the MAPK inhibitors on the internalization of
C. pneumoniae EBs into THP-1 cells was determined by administering
them to the cultures simultaneously with the bacterial inoculum and
determining C. pneumoniae genome copy numbers inside the monocytes
after 2 h incubation. As shown in Fig. 5, the JNK inhibitor SP600125
and the p38 inhibitor SB203580 decreased the C. pneumoniae inter-
nalization statistically significantly, by 40.0% (p = .026) and 37.9%
(p = .035), respectively. The ERK inhibitor FR180204 treatment
yielded 27.5% decrease in internalization, yet it does not reach the
statistical significance. The effect of MAPK inhibitors on EB inter-
nalization seems to have cell type specific characteristics as compara-
tive experiments of EB internalization into HL cells showed no differ-
ence between the MAKP inhibitor treated and not treated samples (data
not shown).
5. Discussion
The propensity for systemic dissemination of C. pneumoniae ties this
bacterium to various chronic inflammatory diseases. The transfer from
the initial bacterial reservoir, the lung epithelium to local phagocytes
and peripheral blood mononuclear cells initiates the dissemination. In
addition, the infection in phagocytes spontaneously confers to an an-
tibiotic-refractory form, significantly hindering the eradication of the
infection. It is thus important to understand the details of epithelial-
phagocyte transition of C. pneumoniae. By blocking it, the burden of
persistent chlamydial infections and their inflammatory consequences
could be reduced. Establishing the coculture assay makes it possible to
evaluate future antichlamydial candidates also for their capability to
block or suppress the transfer of C. pneumoniae between the cell po-
pulations. Furthermore, the optimization of THP-1 cell collection pro-
tocol from the coculture allowed the recovery of viable, C. pneumoniae
infected cells, which makes it possible to follow the fate of the infection
further in these cells.
Separation of the epithelial and monocyte cell populations is an
essential step for reliably quantifying the infection transfer. Detecting
C. pneumoniae from the monocytes requires bacterial quantities
reaching levels that are several orders of magnitude above the PCR
detection limit. This was achieved by allowing the productive infection
in the epithelial cells to proceed for 67 h prior to adding the monocytes.
An alternative means for reaching high C. pneumoniae genome copy
numbers in the monocytes is to allow longer transfer times by in-
creasing the duration of the coculture. This approach is, however,
limited by the tendency of the THP-1 monocytes to adhere on the in-
fected HL cells. Due to this phenomenon, the coculture time was limited
to 5 h, as this time frame resulted in an efficient transfer of the infection
but maintained the two mammalian cell populations relatively easy to
separate from each other. The sensitivity of the C. pneumoniae -specific
PCR detection made the robust quantification of the chlamydial loads in
the monocytes possible shortly after bacterial internalization.
Mitogen-activated protein kinases (MAPK) are the key signaling
molecules in the transduction on the various extracellular stimuli and
they regulate various physiological processes such as transcription and
cell survival (Saba-El-Leil, 2016). MAPKs are activated by signals such
as cytokines, environmental stress and inflammation and they are di-
vided into different groups: extracellular signal-related kinases (ERK),
Jun amino-terminal kinases (JNK) and p38 proteins, and they all can be
activated by different signaling molecules depending on the stimuli.
MAPKs are widely expressed, but the roles of each cascade is highly cell
type dependent (Yasuda, 2015).
Activation of MAP kinase pathways is also a well-established con-
sequence of C. pneumoniae infection (Krüll et al., 2004). Within minutes
after contact with C. pneumoniae EBs, endothelial cells increase the
phosphorylation of ERK1/2, p38 and JNK (Krüll et al., 2005). In mac-
rophages, activation of MAPKs is involved with pathological changes
caused by the infection, such as foam cell formation (Cheng et al.,
2014) and induction of adhesion of monocytes to endothelium (Kaul
and Wenman, 2001). In addition, C. pneumoniae induces immune re-
sponse in peripheral blood mononuclear cells (PBMC) by activating p38
and p44/42 MAPK pathways (Rupp et al., 2004). It has been reported
that p38 inhibitors SB203580 and SB202190 as well as JNK inhibitors
SP600125 and TCSJNK60 inhibit C. pneumoniae inclusion counts in HL
cells when they are present throughout the 72 h infection (Hanski and
Vuorela, 2016). This demonstrates that besides mediating the C. pneu-
moniae induced pathologies in the host, MAPK pathways have a role in
chlamydial replication and maintenance of active growth.
Due to the well-known involvement of MAPKs in Chlamydia – host
interactions, three different MAPK inhibitors (JNK inhibitor SP600125,
p38 inhibitor SB203580 and ERK inhibitor FR180204) were studied for
their impact on epithelial-monocytic transition of C. pneumoniae. Our
results demonstrate that all three studied compounds significantly
suppressed the C. pneumoniae genome copy numbers in THP-1 cells
after coculture and can thus be applied as positive controls for the assay
(Fig. 3).
Compounds that block or suppress the transfer of C. pneumoniae
between the cells can target several distinct points in chlamydial
Fig. 5. MAPK inhibitors suppress the internalization of C. pneumoniae into THP-
1 cells. THP-1 cells were incubated for 2 h with C. pneumoniae and MAPK in-
hibitors to examine the internalization of C. pneumoniae into THP-1 cells. The
bacterial genome copy numbers were determined with qPCR. Data are nor-
malized on the infection control and shown as mean ± SEM of C. pneumoniae
genome numbers. Statistical significance is determined by One-way ANOVA
and Dunnett's post hoc test and presented as marks of P values:< 0.05:
*;< 0.01: **;< 0.001: ***. N = 5 independent biological replicates.
Fig. 4. Impact of MAPK inhibitors on the release of the bacteria from epithelial
cells. HL cells were infected and treated for 5 h with MAPK inhibitors
SP600125, SB203580 and FR180204 at the late state of the replication cycle.
Released EBs were collected and C. pneumoniae GE copy numbers were de-
termined by qPCR. Data are normalized on the infection control and shown as
mean ± SEM of C. pneumoniae genome copy numbers. Statistical significance
is determined by One-way ANOVA and Dunnett's post hoc test and presented as
marks of P values:< 0.05: *;< 0.01: **;< 0.001: ***. n = 6 independent
biological replicates.
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replication cycle. They can block the exit of the EBs from epithelial cells
to extracellular space, inhibit the infectivity of released bacteria or
block the internalization of the EBs into the monocytes. To evaluate the
impact of MAPK inhibitors on these processes, a series of experiments
were carried out. Based on these data, the quantities of C. pneumoniae
EBs inside HL cells was not affected by the 5 h exposure of the cultures
to the MAPK inhibitors at late stage of infection. The differentiation of
RBs back to EBs and their release from the host cells are asynchronous
(Di Pietro et al., 2019). Thus the late stage of the bacterial replication
cycle is characterized by a continuous RB to EB differentiation but
MAPK inhibitors obviously have no role in this process.
Regarding the quantities of C. pneumoniae EBs released to extra-
cellular space, p38 inhibitor SB203580 and ERK inhibitor FR180204
had no effect. In contrast, the JNK inhibitor SP600125 increased the
levels of EBs in the culture supernatants (Fig. 4). In general, the EB
quantities in supernatants were 20-fold lower than in cell lysates, which
provides a plausible explanation why the significant increase in EB
release did not translate into significantly lower EB quantities observed
in the cell lysates.
Based on current knowledge, the exit of Chlamydia spp. bacteria
from their host cells can occur by two different mechanisms: host cell
lysis and extrusion (Hybiske and Stephens, 2007). In lysis, the inclusion
vacuole is first erupted following the host cell plasma membrane
eruption and release of the EBs to extracellular space. Lysis is mediated
by cysteine proteases (Chin et al., 2012) and it has been demonstrated
for several chlamydial species (Hybiske and Stephens, 2007; Rockey
et al., 1996) but in fact, not experimentally demonstrated for C. pneu-
moniae in published literature.
In contrast, exit by extrusion has been experimentally demonstrated
also for C. pneumoniae (Zuck et al., 2016). It represents a process in
which the whole inclusion buds out of the host cell, generating mem-
brane-bound vacuole packed with bacterial cells and leaving the host
cell intact (Hybiske and Stephens, 2007).
To allow the pathogen to orchestrate the cellular events necessary
for extrusion, chlamydial effector proteins secreted through type III
secretion system (T3SS) recruit actin to polymerize and form a coat to
facilitate the extrusion (Chin et al., 2012). Also, MAPKs have a role in
actin polymerization (Coombes and Mahony, 2002) which forms a
potential link between the JNK inhibitor and chlamydial exit. Yet laying
beyond the scope of the current study, the role of JNK in C. pneumoniae
exit from epithelial cells warrants further investigation.
The recent findings on chlamydial exit by extrusion has shed light
also on the extracellular survival and the entry mechanisms of these
obligate intracellular pathogens to phagocytic cells. The extrusion va-
cuole protects the bacteria from immune system effector molecules and
the extrusion-bound chlamydial cells can survive in the extracellular
space much longer than free EBs (Zuck et al., 2017). It has also been
demonstrated that the whole extruded inclusion can be phagocytized by
macrophages, facilitating a secondary infection and migration inside
the body.
In the coculture model, unsheltered EBs or extrusion vacuoles
containing EBs are released from the epithelial cells to extracellular
space and may be affected by the studied compounds. Methods for
isolating the extrusions from the extracellular space have been pre-
viously described (Zuck et al., 2017) and can be applied to study the
impact of compounds of interest on their stability or infectivity. How-
ever, to determine the EB amount accurately and set a defined infection
multiplicity for the internalization assay, we used EBs from a prediluted
stock, instead of extracted extrusions. These experiments revealed no
impact of any of the studied MAPK inhibitors on the infectivity of EBs.
Within the step-by-step evaluation of the epithelium – monocyte
transition, the internalization of EBs into THP-1 cells was suppressed by
the JNK inhibitor SP600125 and p38 inhibitor SB203580 (Fig. 5). These
findings represent previously undescribed activities of MAPK signaling
pathways on chlamydial replication cycle yet they are not surprising
owing to well established connection of MAPK signaling with actin
polymerization. Relying on endocytosis for entering mammalian cells,
actin dynamics is essential for chlamydial entry (Coombes and Mahony,
2002). Blocking another MAPK, MEK1/2, which operates upstream
from ERK, has decreased the C. pneumoniae internalization into Hep2
epithelial cells (Mölleken et al., 2013).
Internalization of C. pneumoniae EBs into the host cells involves
several different proteins from the bacterium and the host (Elwell et al.,
2016). Initiated by the low-affinity interaction of EB adhesion protein,
outer membrane complex protein B (OmcB) with heparin sulfate pro-
teoglycans (HSPGs) (Moelleken and Hegemann, 2008), the endocytosis
is mediated by the interaction of chlamydial surface proteins with
cellular receptors. The receptor type differs between the cell line and
chlamydial strain and various receptors can be involved in attachment
of bacteria (Elwell et al., 2016). Cell surface receptors e.g. mannose 6-
phosphate (Puolakkainen et al., 2005), epidermal growth factor re-
ceptor (EGFR) (Mölleken et al., 2013), insulin-like growth factor 2 re-
ceptor (Puolakkainen et al., 2005), estrogen receptor complex (Krüll
et al., 2005) and apolipoprotein E4 (Gérard et al., 2008) have been
related to binding of C. pneumoniae to host cells. EGFR remains, how-
ever, the only cellular receptor whose direct contact with C. pneumoniae
adhesins has been demonstrated (Mölleken et al., 2013).
In phagocytes, innate immune sensors Toll like receptors (TLR) 2, 3
and 4, and Nod-like receptors recognize C. pneumoniae and trigger pro-
inflammatory reactions (Abdul-Sater et al., 2010). TLRs trigger a
MYD88 mediated MAPK pathway phosphorylation, leading to activa-
tion of JNK, p38 and ERK kinases in these cells (Krüll et al., 2004).
Despite the well-established role of TLRs in promoting the in-
flammatory responses, it still remains unknown which receptors med-
iates the internalization of Chlamydia into immune cells (Lausen et al.,
2019).
As described above, macrophages are able, in addition to free EBs,
to internalize the whole extrusion vacuole. The extrusions are taken up
by phagocytic cells by actin dependent phagocytosis. Owing to their
surface-exposed phosphatidylserine (PS), extrusions resemble extra-
cellular apoptotic bodies which has been suggested to facilitate their
recognition and internalization by phagocytes. The monocytic THP-1
cells are capable of phagocytosis (Schwende et al., 1996; Tsuchiya
et al., 1980), and the bacterial internalization into them in the coculture
model may involve both unsheltered and extrusion-packed EBs. This
may also explain the greater suppression of epithelium – monocyte
transition by the MAPK inhibitors than what is expected by the step-by-
step analysis of individual phases of the process. This feature also de-
monstrates the added value of the coculture assay compared to analyses
of separate steps. Allowing the direct interactions of the bacterium and
its host cell populations brings in an additional layer of complexity and
contributes to the biological relevance of the results.
6. Conclusions
We report here a new method for studying the epithelial monocytic
transition of C. pneumoniae, an obligate intracellular pathogen. C.
pneumoniae transfer spontaneously into monocytes from epithelial cells
also in vitro and the bacterial transition can be reproducibly quantified
by qPCR.
This coculture platform is useful for studying the mechanisms of
different phases of epithelium-monocyte transition as well as evaluating
new treatment options for C. pneumoniae infections.
MAPK inhibitors can be applied as positive control in these co-
culture studies as they are blocking the transfer of C. pneumoniae pos-
sible by inhibiting the internalization of the bacteria. Our findings
concerning the ability of JNK inhibitors to increase the exit of EBs from
THP-1 cells is interesting and may be related to a different outcome of
activation of MAPKs between the cell types but needs further in-
vestigation.
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